Epidermal growth factor receptor expression in carcinoma gallbladder: A prospective study in Indian scenario

Kumar, Nidhish; Khan, Majid; Kumar, Nishith; Rigvardhan,; Ranjan, Richa; Hazra, Nandita

doi:10.4103/0973-1482.179063

Cited by 7 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Higher EGFR levels in patients could be correlated with shorter survival times [49]. Elevated EGFR levels in GBC can be considered as an independent prognostic variable among patients and can be an indication of adverse prognosis [55,56]. In another study, EGFR was overexpressed in 16% of GBC samples but was not observed in extrahepatic and intrahepatic bile duct cancer samples or normal epithelia or cholecystitis.…”

Section: Egfrmentioning

confidence: 97%

“…EGFR protein overexpression studied through IHC was generally scored as follows: 0= no staining observed; 1+= faint membrane staining in > 1% of cancer cells in part of the cell membrane; 2+= weak to moderate complete • 1034 membrane staining in over 1% of cancer cells; Score 3+= intense complete membrane staining in over 1% of tumour cells [54,56]. Though, EGFR overexpression in GBC has been established through several studies, a standardized approach to quantifying the same is yet to be developed.…”

Section: Egfrmentioning

confidence: 99%

See 1 more Smart Citation

Clinicopathological And Prognostic Significance Of Immuno-Expression Of Cyclin D1, E-Cadherin, EGFR, HER- 2, Ki67, And P53 In Gall Bladder Cancer And Its Precursor Lesions-A Review

Agarwal¹

2022

Journal of Pharmaceutical Negative Results

View full text Add to dashboard Cite

Gallbladder carcinoma (GBC) is an aggressive and common cancer of the biliary tract. It develops on the epithelia of the gallbladder and is has the ability to rapidly metastasize to nearby organs and distant lymph nodes. It also has the shortest median survival time when compared to other biliary tract cancers [1]. As the disease rarely presents a distinct set of clinical symptoms, delayed diagnosis contributes heavily towards the negative prognosis widely associated with the disease [2]. The molecular mechanisms and underlying changes that bring about carcinogenesis of the gallbladder epithelia, though widely studied have not been fully understood. Chronic inflammation [3], dysplasia [4] and adenoma [5] among other factors have been observed to increase the risk of developing GBC among other risk factors. With current treatment options offering only limited curative capacities, identifying and studying biomarkers with potential to speed up prognostics and having clinical applicability has become a priority. These biomarkers, apart from playing an important role in carcinogenesis, need to be specific for GBC and their levels should vary significantly enough to differentiate between malignant and benign conditions. Though several such molecules have been identified and used in diagnostic trials, the availability of disease-specific and highly sensitive markers for GBC is yet a task to be achieved. Isolation of such prognostic markers will help in understanding disease progression [6]. Further, expression levels of these prognostic markers can be used to aid in the determination of the clinical course of action, patient response to therapy and the need for adjuvant therapy [7]. An ideal prognostic marker should be easily quantifiable with high sensitivity, specificity and its levels should significantly vary to be able to differentiate benign conditions from malignancy. A clinically applicable prognostic marker should be able to predict recurrence, survivability and need for adjuvant therapies. Several categories of markers have been studied to date and include tumour markers such as CA125, CA19-9, CEA, inflammatory markers like CRP, tumour suppressors like p53, E-cadherin etc. In this review we hope to explore the future prospects of some of these markers based on available literature.

show abstract

Section: Egfrmentioning

confidence: 97%

Section: Egfrmentioning

confidence: 99%

Clinicopathological And Prognostic Significance Of Immuno-Expression Of Cyclin D1, E-Cadherin, EGFR, HER- 2, Ki67, And P53 In Gall Bladder Cancer And Its Precursor Lesions-A Review

Agarwal¹

2022

Journal of Pharmaceutical Negative Results

View full text Add to dashboard Cite

show abstract

Section: Cyclin D1mentioning

confidence: 99%

“…EGFR protein overexpression studied through IHC was generally scored as follows: 0= no staining observed; 1+= faint membrane staining in > 1% of cancer cells in part of the cell membrane; 2+= weak to moderate complete membrane staining in over 1% of cancer cells; Score 3+= intense complete membrane staining in over 1% of tumour cells [28,30]. Though, EGFR overexpression in GBC has been established through several studies, a standardized approach to quantifying the same is yet to be developed.…”

Section: Cyclin D1mentioning

confidence: 99%

“…The most commonly used scoring systems in these studies are based on the criteria used for gastric cancer [40] and breast cancer [38][39][40][41] along with the Hercep test scoring system [28][29][30][31][32][33][34][35][36][37][38][39][40][41][42]. Though, Toledo et al argued that HER2 immunoreactivity observed in basolateral cell membrane domain of metaplastic gallbladder epithelium in GBC could not be compared to that scored by Hercep Test as it is based on the immunoreactivity observed in invasive breast cancer cells that are neoplastic non-polarized cells, Kawamato et al suggested that Hercep test could be used as an acceptable predictor to determine FISH positivity of HER2 gene amplification [28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43]. It has also been suggested that HER2 overexpression could be more prevalent in precursor lesions than carcinoma in situ and metastasis [30,[44][45].…”

Section: Her2mentioning

confidence: 99%

See 1 more Smart Citation

A Study of Cyclin D1, E-cadherin, EGFR, HER- 2, Ki67, and p53 Tumor Marker Expressions in Neoplastic and Non -neoplastic Gall Bladder Lesions and their Clinico-pathological Correlation

Agarwal

Bansal

Gupta

2022

ijmsdr

View full text Add to dashboard Cite

Background: Worldwide gall bladder cancer (GBC) is known to be the commonest malignant tumour of the biliary tract. It is the most aggressive carcinoma of the biliary tract with short median survival from the time of diagnosis. The aggressive biologic behaviour of the carcinoma and non-availability of sensitive screening tests for early detection may be responsible for the poor prognosis associated with GBC. Material and Methods: Patients diagnosed with neoplastic and non-neoplastic gallbladder lesions in the Department of Pathology, Subharti Medical College in India were included in the study. Gall bladder biopsies findings and the clinic-pathological data were compiled and different immune-markers diagnostic and therapeutic usefulness were studied . Results: 24 (24.0%) of the cases were in the age group of 51-60 Years. In 38 (38.0%) of the cases the site of lesion was Fundus. 55 (55.0%) of cases had associated stones. 36 (36.0%) of them had P53: strong over expression, 40 (40.0%) of the them had ki67: strong over expression, 25 (25.0%) had EGFR: strong over expression whereas negative expression for Her2/Neu was found in 61 (61.0%) of the cases. Cyclin D1: moderate over expression was found in 27 (27.0%) of them and moderate over expression of E-cadherin were found in 22 (23.2%) cases. Conclusions: Novel prognostic biomarkers could bring about the needed breakthrough in gall bladder cancer diagnosis and treatment. We conclude that the biomarkers studied by us may help in the identification of cases who may benefit tremendously from adjuvant and targeted therapies. Key words: Cyclin D1, E-cadherin, EGFR, HER- 2, Ki67, p53, tumour marker, neoplastic , non –neoplastic, Gall bladder lesions.

show abstract

EGFR signaling pathway occupies an important position in cancer‐related downstream signaling pathways of Pyk2

Shen

Guo

2019

Cell Biology International

View full text Add to dashboard Cite

Proline‐rich tyrosine kinase 2 (Pyk2) is a member of focal adhesion kinase (FAK) non‐receptor tyrosine kinase family and has been found to promote cancer cell survival, proliferation, migration, invasion, and metastasis. Pyk2 takes part in different carcinogenic signaling pathways to promote cancer progression, including epidermal growth factor receptor (EGFR) signaling pathway. EGFR signaling pathway is a traditional carcinogenic signaling pathway, which plays a critical role in tumorigenesis and tumor progression. FAK inhibitors have been reported to fail to get the ideal anti‐cancer outcomes because of activation of EGFR signaling pathway. Better understanding of Pyk2 downstream targets and interconnectivity between Pyk2 and carcinogenic EGFR signaling pathway will help finding more effective targets for clinical anti‐cancer combination therapies. Thus, the interconnectivity between Pyk2 and EGFR signaling pathway, which regulates tumor development and metastasis, needs to be elucidated. In this review, we summarized the downstream targets of Pyk2 in cancers, focused on the connection between Pyk2 and EGFR signaling pathway in different cancer types, and provided a new overview of the roles of Pyk2 in EGFR signaling pathway and cancer development.

show abstract

Epidermal growth factor receptor expression in carcinoma gallbladder: A prospective study in Indian scenario

Cited by 7 publications

References 0 publications

Clinicopathological And Prognostic Significance Of Immuno-Expression Of Cyclin D1, E-Cadherin, EGFR, HER- 2, Ki67, And P53 In Gall Bladder Cancer And Its Precursor Lesions-A Review

Clinicopathological And Prognostic Significance Of Immuno-Expression Of Cyclin D1, E-Cadherin, EGFR, HER- 2, Ki67, And P53 In Gall Bladder Cancer And Its Precursor Lesions-A Review

A Study of Cyclin D1, E-cadherin, EGFR, HER- 2, Ki67, and p53 Tumor Marker Expressions in Neoplastic and Non -neoplastic Gall Bladder Lesions and their Clinico-pathological Correlation

EGFR signaling pathway occupies an important position in cancer‐related downstream signaling pathways of Pyk2

Contact Info

Product

Resources

About